DaVita
DVA
#2199
Rank
โ‚น752.65 B
Marketcap
โ‚น10,527
Share price
-0.29%
Change (1 day)
-21.34%
Change (1 year)
DaVita Inc. is an American company providing dialysis services for patients with chronic and acute kidney failure.

P/E ratio for DaVita (DVA)

P/E ratio as of December 2025 (TTM): 11.8

According to DaVita's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 11.7757. At the end of 2024 the company had a P/E ratio of 13.6.

P/E ratio history for DaVita from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202413.6-1.51%
202313.810.25%
202212.51.86%
202112.3-32.76%
202018.230.72%
201913.9-77.24%
201861.3197.62%
201720.639.47%
201614.8-73.11%
201554.9147.85%
201422.15.37%
201321.05.73%
201219.9

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Tenet Healthcare
THC
14.0 19.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Pediatrix Medical Group
MD
11.4-3.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Universal Health Services
UHS
10.6-10.06%๐Ÿ‡บ๐Ÿ‡ธ USA
LabCorp
LH
25.4 115.36%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.